A citation-based method for searching scientific literature

Benedikt C Westphalen, Carsten Bokemeyer, Reinhard Büttner, Stefan Fröhling, Verena I Gaidzik, Hanno Glimm, Ulrich T Hacker, Volker Heinemann, Anna L Illert, Ulrich Keilholz, Thomas Kindler, Martin Kirschner, Bastian Schilling, Jens T Siveke, Thomas Schroeder, Verena Tischler, Sebastian Wagner, Wilko Weichert, Daniel Zips, Sonja Loges. Eur J Cancer 2020
Times Cited: 12







List of co-cited articles
43 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer.
Nicholas Turner, Alex Pearson, Rachel Sharpe, Maryou Lambros, Felipe Geyer, Maria A Lopez-Garcia, Rachael Natrajan, Caterina Marchio, Elizabeth Iorns, Alan Mackay,[...]. Cancer Res 2010
485
8

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Ghassan K Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew S Paulson, Mitesh J Borad, David Gallinson, Adrian G Murphy,[...]. Lancet Oncol 2020
413
8

ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma.
Naoya Miyashita, Masafumi Horie, Yu Mikami, Hirokazu Urushiyama, Kensuke Fukuda, Kazuko Miyakawa, Hirotaka Matsuzaki, Kosuke Makita, Yasuyuki Morishita, Hiroaki Harada,[...]. Cancer Lett 2020
6
16

Comparative analysis of the tumor immune-microenvironment of primary and brain metastases of non-small-cell lung cancer reveals organ-specific and EGFR mutation-dependent unique immune landscape.
Seung Geun Song, Sehui Kim, Jaemoon Koh, Jeemin Yim, Bogyeong Han, Young A Kim, Yoon Kyung Jeon, Doo Hyun Chung. Cancer Immunol Immunother 2021
7
14

FGFR1 expression and gene copy numbers in human lung cancer.
Lukas H Kohler, Masoud Mireskandari, Thomas Knösel, Annelore Altendorf-Hofmann, Almut Kunze, Andreas Schmidt, Norbert Presselt, Yuan Chen, Iver Petersen. Virchows Arch 2012
50
8

Targeted therapies for advanced non-small-cell lung cancer: current status and future implications.
Ana Custodio, Míriam Méndez, Mariano Provencio. Cancer Treat Rev 2012
49
8

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Martin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, Alejandro Navarro, Ross A Soo, Heike Richly, Philippe Alexandre Cassier, David Tai, Nicolas Penel, Lucia Nogova,[...]. Lancet Oncol 2019
77
8

Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger, Daisy Dai, Brendan Horton, Thomas F Gajewski. Cancer Cell 2017
633
8

Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma.
Clare E Weeden, Aliaksei Z Holik, Richard J Young, Stephen B Ma, Jean-Marc Garnier, Stephen B Fox, Phillip Antippa, Louis B Irving, Daniel P Steinfort, Gavin M Wright,[...]. Mol Cancer Ther 2017
16
8

Profiling cancer testis antigens in non-small-cell lung cancer.
Dijana Djureinovic, Björn M Hallström, Masafumi Horie, Johanna Sofia Margareta Mattsson, Linnea La Fleur, Linn Fagerberg, Hans Brunnström, Cecilia Lindskog, Katrin Madjar, Jörg Rahnenführer,[...]. JCI Insight 2016
64
8

Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer.
Eva Pros, Sylvie Lantuejoul, Lydia Sanchez-Verde, Sandra D Castillo, Ester Bonastre, Ana Suarez-Gauthier, Esther Conde, Juan C Cigudosa, Fernando Lopez-Rios, Juan Torres-Lanzas,[...]. Int J Cancer 2013
22
8

Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Xiuning Le, Marcelo V Negrao, Alexandre Reuben, Lorenzo Federico, Lixia Diao, Daniel McGrail, Monique Nilsson, Jacqulyne Robichaux, Irene Guijarro Munoz, Sonia Patel,[...]. J Thorac Oncol 2021
29
8

The Immune Landscape of Cancer.
Vésteinn Thorsson, David L Gibbs, Scott D Brown, Denise Wolf, Dante S Bortone, Tai-Hsien Ou Yang, Eduard Porta-Pardo, Galen F Gao, Christopher L Plaisier, James A Eddy,[...]. Immunity 2018
8

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
Charu Aggarwal, Mary W Redman, Primo N Lara, Hossein Borghaei, Philip Hoffman, Jeffrey D Bradley, Alfred J Newman, Marvin J Feldman, Katherine Minichiello, Jieling Miao,[...]. J Thorac Oncol 2019
41
8

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.
Young K Chae, Fangxin Hong, Christos Vaklavas, Heather H Cheng, Peter Hammerman, Edith P Mitchell, James A Zwiebel, S Percy Ivy, Robert J Gray, Shuli Li,[...]. J Clin Oncol 2020
43
8

Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
H Kotani, H Ebi, H Kitai, S Nanjo, K Kita, T G Huynh, A Ooi, A C Faber, M Mino-Kenudson, S Yano. Oncogene 2016
31
8

Multispectral imaging for quantitative and compartment-specific immune infiltrates reveals distinct immune profiles that classify lung cancer patients.
Artur Mezheyeuski, Christian Holst Bergsland, Max Backman, Dijana Djureinovic, Tobias Sjöblom, Jarle Bruun, Patrick Micke. J Pathol 2018
85
8

The Hippo/YAP1 pathway interacts with FGFR1 signaling to maintain stemness in lung cancer.
Tingting Lu, Ziming Li, Ying Yang, Wenxiang Ji, Yongfeng Yu, Xiaomin Niu, Qingyu Zeng, Weiliang Xia, Shun Lu. Cancer Lett 2018
32
8

Integrative analysis of genome-wide gene copy number changes and gene expression in non-small cell lung cancer.
Verena Jabs, Karolina Edlund, Helena König, Marianna Grinberg, Katrin Madjar, Jörg Rahnenführer, Simon Ekman, Michael Bergkvist, Lars Holmberg, Katja Ickstadt,[...]. PLoS One 2017
37
8

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.
Robin L Jones, Mark J Ratain, Peter J O'Dwyer, Lillian L Siu, Jacek Jassem, Jacques Medioni, Maja DeJonge, Charles Rudin, Michael Sawyer, David Khayat,[...]. Eur J Cancer 2019
14
8

Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients.
André Kahles, Kjong-Van Lehmann, Nora C Toussaint, Matthias Hüser, Stefan G Stark, Timo Sachsenberg, Oliver Stegle, Oliver Kohlbacher, Chris Sander, Gunnar Rätsch. Cancer Cell 2018
329
8

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Yohann Loriot, Andrea Necchi, Se Hoon Park, Jesus Garcia-Donas, Robert Huddart, Earle Burgess, Mark Fleming, Arash Rezazadeh, Begoña Mellado, Sergey Varlamov,[...]. N Engl J Med 2019
472
8

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.
Hans-Ulrich Schildhaus, Lukas C Heukamp, Sabine Merkelbach-Bruse, Katharina Riesner, Katja Schmitz, Elke Binot, Ellen Paggen, Kerstin Albus, Wolfgang Schulte, Yon-Dschun Ko,[...]. Mod Pathol 2012
99
8

Fibroblast growth factor signalling: from development to cancer.
Nicholas Turner, Richard Grose. Nat Rev Cancer 2010
8

Comparison of scores for bimodality of gene expression distributions and genome-wide evaluation of the prognostic relevance of high-scoring genes.
Birte Hellwig, Jan G Hengstler, Marcus Schmidt, Mathias C Gehrmann, Wiebke Schormann, Jörg Rahnenführer. BMC Bioinformatics 2010
39
8

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity.
Jude Canon, Karen Rex, Anne Y Saiki, Christopher Mohr, Keegan Cooke, Dhanashri Bagal, Kevin Gaida, Tyler Holt, Charles G Knutson, Neelima Koppada,[...]. Nature 2019
713
8

Genomic alterations in lung adenocarcinoma.
Siddhartha Devarakonda, Daniel Morgensztern, Ramaswamy Govindan. Lancet Oncol 2015
201
8

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study.
Lucia Nogova, Lecia V Sequist, Jose Manuel Perez Garcia, Fabrice Andre, Jean-Pierre Delord, Manuel Hidalgo, Jan H M Schellens, Philippe A Cassier, D Ross Camidge, Martin Schuler,[...]. J Clin Oncol 2017
255
8

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors.
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, Yohann Loriot, Ken A Olaussen, Christophe Massard, Luc Friboulet. Clin Cancer Res 2020
45
8


MiR-16 regulates the pro-tumorigenic potential of lung fibroblasts through the inhibition of HGF production in an FGFR-1- and MEK1-dependent manner.
Francesca Andriani, Maria Teresa Majorini, Miguel Mano, Elena Landoni, Rosalba Miceli, Federica Facchinetti, Mavis Mensah, Enrico Fontanella, Matteo Dugo, Mauro Giacca,[...]. J Hematol Oncol 2018
15
8

Various Antibody Clones of Napsin A, Thyroid Transcription Factor 1, and p40 and Comparisons With Cytokeratin 5 and p63 in Histopathologic Diagnostics of Non-Small Cell Lung Carcinoma.
Lena Tran, Johanna S M Mattsson, Björn Nodin, Per Jönsson, Maria Planck, Karin Jirström, Johan Botling, Patrick Micke, Hans Brunnström. Appl Immunohistochem Mol Morphol 2016
19
8

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers.
Paul K Paik, Ronglai Shen, Michael F Berger, David Ferry, Jean-Charles Soria, Alastair Mathewson, Claire Rooney, Neil R Smith, Marie Cullberg, Elaine Kilgour,[...]. Clin Cancer Res 2017
87
8

recount workflow: Accessing over 70,000 human RNA-seq samples with Bioconductor.
Leonardo Collado-Torres, Abhinav Nellore, Andrew E Jaffe. F1000Res 2017
27
8

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.
Zhong-Yi Dong, Jia-Tao Zhang, Si-Yang Liu, Jian Su, Chao Zhang, Zhi Xie, Qing Zhou, Hai-Yan Tu, Chong-Rui Xu, Li-Xu Yan,[...]. Oncoimmunology 2017
200
8

Characterization of FGFR1 Locus in sqNSCLC Reveals a Broad and Heterogeneous Amplicon.
Claire Rooney, Catherine Geh, Victoria Williams, Johannes M Heuckmann, Roopika Menon, Petra Schneider, Katherine Al-Kadhimi, Michael Dymond, Neil R Smith, Dawn Baker,[...]. PLoS One 2016
14
8

A novel monovalent FGFR1 antagonist: Preclinical safety profiles in rodents and non-human primates.
Ping Yu, Anja Knippel, Manuela Onidi, Andrea Paoletti, Enrico Vigna, Juergen Hellmann, Christina Esdar. Toxicol Appl Pharmacol 2020
1
100

Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases.
Kenichi Suda, Tetsuya Mitsudomi, Yasushi Shintani, Jiro Okami, Hiroyuki Ito, Takashi Ohtsuka, Shinichi Toyooka, Takeshi Mori, Shun-Ichi Watanabe, Hisao Asamura,[...]. Ann Thorac Surg 2021
22
8

The biology and treatment of EML4-ALK non-small cell lung cancer.
Takaaki Sasaki, Scott J Rodig, Lucian R Chirieac, Pasi A Jänne. Eur J Cancer 2010
376
8

Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression.
Johanna S M Mattsson, Bengt Bergman, Marianna Grinberg, Karolina Edlund, Millaray Marincevic, Karin Jirström, Fredrik Pontén, Jan G Hengstler, Jörg Rahnenführer, Mats G Karlsson,[...]. Cancer Lett 2015
19
8

KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.
Francesco Passiglia, Umberto Malapelle, Marzia Del Re, Luisella Righi, Fabio Pagni, Daniela Furlan, Romano Danesi, Giancarlo Troncone, Silvia Novello. Eur J Cancer 2020
19
8

The Impact of the Fourth Edition of the WHO Classification of Lung Tumours on Histological Classification of Resected Pulmonary NSCCs.
Patrick Micke, Johanna Sofia Margareta Mattsson, Dijana Djureinovic, Björn Nodin, Karin Jirström, Lena Tran, Per Jönsson, Maria Planck, Johan Botling, Hans Brunnström. J Thorac Oncol 2016
49
8

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
203
8

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, Yvonne Y Li, Amir R Aref, Ferdinandos Skoulidis, Grit S Herter-Sprie, Kevin A Buczkowski, Yan Liu, Mark M Awad, Warren L Denning,[...]. Cancer Res 2016
313
8

BCL2 and miR-15/16: from gene discovery to treatment.
Yuri Pekarsky, Veronica Balatti, Carlo M Croce. Cell Death Differ 2018
98
8

TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Jérôme Biton, Audrey Mansuet-Lupo, Nicolas Pécuchet, Marco Alifano, Hanane Ouakrim, Jennifer Arrondeau, Pascaline Boudou-Rouquette, François Goldwasser, Karen Leroy, Jeremy Goc,[...]. Clin Cancer Res 2018
160
8

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Jingchuan Zhang, Lin Zhang, Xinying Su, Ming Li, Liang Xie, Florian Malchers, ShuQiong Fan, XiaoLu Yin, YanPing Xu, Kunji Liu,[...]. Clin Cancer Res 2012
126
8

The sequence of sequencers: The history of sequencing DNA.
James M Heather, Benjamin Chain. Genomics 2016
316
8

Pseudogenes are not pseudo any more.
Yan-Zi Wen, Ling-Ling Zheng, Liang-Hu Qu, Francisco J Ayala, Zhao-Rong Lun. RNA Biol 2012
28
8

The repertoire of mutational signatures in human cancer.
Ludmil B Alexandrov, Jaegil Kim, Nicholas J Haradhvala, Mi Ni Huang, Alvin Wei Tian Ng, Yang Wu, Arnoud Boot, Kyle R Covington, Dmitry A Gordenin, Erik N Bergstrom,[...]. Nature 2020
864
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.